

# The Neurobiology, Physiology, and Psychology of Pain

The Neuroscience of Pain, Anesthetics,  
and Analgesics

---

Edited by

**Rajkumar Rajendram**

Department of Medicine, King Abdulaziz Medical City, King Abdulaziz International Medical Research Center, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia

College of Medicine, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Saudi Arabia

**Vinood B. Patel**

Centre for Nutraceuticals, School of Life Sciences, University of Westminster, London, United Kingdom

**Victor R. Preedy**

King's College London, London, United Kingdom

**Colin R. Martin**

Institute for Health and Wellbeing, University of Suffolk, United Kingdom



**ACADEMIC PRESS**

An imprint of Elsevier

# Contents

Contributors	xv		
Preface	xxi		
<b>Part I</b>			
<b>Molecular and cellular aspects</b>			
<b>1. KCNQ/Kv7 channels as therapeutic target to treat neuropathic pain</b>			
<i>Zizhen Wu and Qing Yang</i>			
Introduction	3		
KCNQ/Kv7 channel family members	3		
KCNQ proteins and function	3		
KCNQ channel compositions	4		
KCNQ channels in primary sensory neurons and their contribution to neuropathic pain	5		
Primary sensory neurons and neuropathic pain	5		
KCNQ channels in primary sensory neurons	6		
Plasticity of KCNQ channels and their contribution to neuropathic pain	6		
<b>KCNQ channels as therapeutic target to treat neuropathic pain</b>	7		
KCNQ channels as therapeutic target to treat established pain	7		
KCNQ channels as therapeutic target to prevent the development of neuropathic pain	8		
Challenges	8		
Applications to other areas	9		
Other agents of interest	10		
Mini-dictionary of terms	10		
Key facts of KCNQ/Kv7 channels and neuropathic pain	10		
Summary points	10		
References	10		
<b>2. A new mutation in <i>NTRK1</i> gene is associated with congenital insensitivity to pain without anhidrosis</b>			
<i>Mogge Hajiesmaeil, Fatemeh Yazarlou, Maryam Sobhani, and Soudeh Ghafouri-Fard</i>			
Introduction		13	
The applications to other areas		19	
Mini-dictionary of terms		19	
Key facts		20	
Summary points		20	
References		20	
<b>3. Prdm12, a key transcriptional regulator of the nociceptive lineage</b>			
<i>Simon Vermeiren, Simon Desiderio, and Eric J. Bellefroid</i>			
Introduction		23	
Painlessness genes		24	
Mutations in <i>PRDM12</i> cause CIP and midface toddler excoriation syndrome		25	
Prdm12 is selectively expressed in developing somatosensory ganglia in the nociceptive lineage		26	
Prdm12 is essential for the emergence of the entire nociceptive lineage		26	
How does Prdm12 function in the specification and maturation of nociceptive neurons?		26	
Does Prdm12 play a role in mature nociceptors?		27	
Applications to other areas		28	
Other agents of interest		28	
Mini-dictionary of terms		29	
Key facts showing the importance of Prdm12 in nociceptors		29	
Summary points		29	
References		29	

#### 4. Genetics of chronic widespread musculoskeletal pain

*María Jesús Álvarez-Cubero,  
Sergio Cuenca-López,  
Verónica Arenas-Rodríguez,  
Fernando Estévez-López, and  
Luis Javier Martínez-González*

Introduction	33
Heritability of chronic widespread musculoskeletal pain	34
Candidate gene studies in chronic widespread musculoskeletal pain	34
Case-control studies	35
Association genotype-phenotype SNPs that has been studied in only one analysis in fibromyalgia	38
GWAS	39
Interactions.(gene-gene and gene-environment)	39
Future perspectives (mainly, research agenda)	40
Applications to other areas	41
Mini-dictionary of terms	41
Key facts	41
Summary points	41
References	41

#### 5. Fentanyl: Polymorphisms, and adverse events

*Mongi Benjeddou and Ana M. Peiró*

Opioid fentanyl use in pain management	45
Fentanyl pharmacology	46
Fentanyl safety profile	47
Fentanyl misuse and abuse	48
Potential pharmacogenetics markers in fentanyl pain management	49
Candidate genes	50
Barriers to implementation	52
Conclusions	53
Applications to other areas	53
Other agents of interest	53
Mini-dictionary of terms	53
Key facts of fentanyl	54
Summary points	54
References	54

#### 6. Propofol anesthesia and molecular changes in the brain

*Desanka Milanović, Željko Pavković,  
and Vesna Pešić*

Introduction	57
Formulation matter	58

Neural and molecular targets of propofol	58
Propofol-induced brain molecular changes during postanesthesia period	59
Molecular changes that reflect alterations in neuronal activity at the peak of brain growth spurt	59
Age-dependent peculiarities in the expression of neurotrophins and their downstream signaling pathways	59
Neuronal activity and synaptic plasticity	60
Molecular autograph of longer exposures to propofol at the peak of the brain growth spurt	61
Propofol and age-related brain pathology	61
Applications to other areas	61
Other agents of interest	62
Mini-dictionary of terms	62
Key facts of propofol anesthesia and molecular changes in the brain	63
Summary points	64
References	64

#### 7. Protein kinase G is a molecular switch for pain

*Ying-Ju Sung and Richard T. Ambron*

Introduction	67
Pain is perceived via inputs from nociceptive circuits that are adaptive	67
Nociception	67
The acute perception of pain	68
The prolonged perception of pain	68
Long-term potentiation	68
LTH and persistent pain	69
Distinction between persistent and chronic pain	70
LTH is induced by protein kinase G, a positive injury signal in nociceptive neurons	70
PKG-1 $\alpha$ is a nociceptive positive injury signal for LTH in rats	70
Persistent activity of PKG-1 $\alpha$ in sensory neurons after nerve injury in rats	71
Development of a novel potent PKG inhibitor	72
N46 effectively alleviates chronic osteoarthritic and inflammation-induced pain	74
Side effects and the fate of N46 in vivo	74
Conclusions	75
Applications to other areas	75
Other agents of interest	75
Mini-dictionary of terms	75

Key facts	75	PET imaging confirms pain-induced alterations of ORs in the MCLS during pain	94
Summary points	75	Preclinical studies show altered MOR density or function derived from the presence of pain	94
References	76	Animal models of pain showed altered DA-related behaviors derived from the pharmacological activation of MORs	96
<b>8. Adrenergic agonists and antagonists enhance opioid receptor activity</b>		Inflammatory pain promotes increased opioid self-administration	98
<i>Robert Root-Bernstein</i>		Dynorfin/KOR system (Dyn/KOR) of the MCLS: A new key player in pain field	98
Introduction	79	Applications to other areas	98
Anatomical and cellular codistribution of opioid and adrenergic functions	79	Mini-dictionary of terms	100
Mechanisms of adrenergic receptor-opioid receptor cross-talk	80	Key facts of pain-induced changes in OR function	100
Opioids bind to adrenergic receptors	80	Summary points	100
Adrenergic compounds bind to opioid receptors	80	References	100
Opioid receptor-adrenergic receptor heterodimerization	81		
A model of adrenoceptor-opioid receptor cross-talk	81	<b>10. <i>Clinacanthus nutans</i> L., analgesia, and the L-arginine/nitric oxide-mediated/cyclic-guanosine monophosphate-independent pathway</b>	
Synergistic effects of adrenergic-opioid receptor cross-talk in the treatment of pain	84	<i>Zainul Amiruddin Zakaria</i>	
Prevention of desensitization and mutual resensitization of opioid and adrenergic receptor function by each other's ligands	84	Introduction	104
Applications to other areas: Local anesthetic enhancement and opioid sparing uses	85	Herbal remedies for the treatment of pain	104
Other agents of interest: Ascorbic acid, tramadol and tapentadol, and ketamine	85	<i>Clinacanthus nutans</i> L.	104
Mini-dictionary of terms	86	Report on findings related to the antinociceptive activity of <i>C. nutans</i>	104
Key facts	86	Antinociceptive profile of MCNL and the possible mechanisms of antinociception	104
Summary points	86	Antinociceptive profile of PEP and the possible mechanisms of antinociception	106
References	86	Phytoconstituents of MCNL and PEP	107
<b>9. Inflammatory and neuropathic pain impact on the opioid function in the mesocorticolimbic system</b>		Conclusion based on the reported antinociceptive activity of MCNL and PEP	107
<i>Yolanda Campos-Jurado, Javier Cuitavi, Natalia Landsberg, Jesús D. Lorente, and Lucia Hipólito</i>		Involvement of peripheral and central antinociceptive mechanisms	108
Introduction	91	Involvement of various mechanisms of antinociception	109
A short introduction to the opioid receptors	92	Role of general opioidergic system	109
The endogenous opioid system: A key component of analgesia, reward, and aversion	92	Involvement of specific opioidergic system subtypes	110
Chronic pain alters brain function and connectivity recruiting motivational and emotional regions	92	Role of nonopioidergic systems	110
		Involvement of transient receptor potential vanilloid type 1 (TRPV1) receptors, glutamatergic system, protein kinase C (PKC)-mediated pathway, and bradykininergic system	110

Involvement of $\alpha$ 2-adrenergic, $\beta$ -adrenergic, adenosinergic, dopaminergic, or muscarinic cholinergic receptor systems	110	Expression of $\alpha$ 5GABA <sub>A</sub> receptors at spinal cord and DRG	130
Involvement of various types of K <sup>+</sup> channels	111	GABAergic tonic current in the spinal cord	130
Role of NO-mediated pathways	111	GABAergic tonic current in spinal cord in mammals	132
Applications to other areas	111	Extrasynaptic $\alpha$ 5GABA <sub>A</sub> receptors in the rate-dependent depression (RDD) of the Hoffmann reflex (HR)	132
Other agents of interest	112	Function of extrasynaptic $\alpha$ 5GABA <sub>A</sub> receptors in primary afferent fibers	133
Mini-dictionary of terms	112	Extrasynaptic spinal $\alpha$ 5GABA <sub>A</sub> receptors in pain	133
Key facts	113	Extrasynaptic $\alpha$ 5GABA <sub>A</sub> receptors regulation	133
Key facts of analgesia	113	Applications to other areas	133
Summary points	113	Other agents of interest	135
References	113	Mini-dictionary of terms	135
		Key facts on $\alpha$ 5GABA <sub>A</sub> receptors in pain	135
<b>11. The orally bioavailable imidazodiazepine, KRM-II-81, is a novel potentiator of <math>\alpha</math>2/3-containing GABA<sub>A</sub> receptors with analgesic efficacy</b>		Summary points	135
<i>Rok Cerne, Jodi L. Smith, Janet L. Fisher, Lalit K. Golani, Daniel E. Knutson, James M. Cook, and Jeffrey M. Witkin</i>		Acknowledgments	136
Introduction	117	References	136
GABA receptors	117	<b>13. ATP-sensitive potassium channels in pain and analgesia</b>	
GABA <sub>A</sub> receptor potentiating benzodiazepines and pain	118	<i>Taís de Campos Lima, Débora de Oliveira Santos, and Celina Monteiro da Cruz Lotufo</i>	
Alpha 2/3-containing GABA <sub>A</sub> receptors	118	ATP-sensitive potassium channels (Katp)	139
KRM-II-81	120	Possible role for Katp channels in primary nociceptive neurons during hyperglycemia	141
KRM-II-81 and pain	120	Katp involvement in the mechanisms of analgesic substances	143
Side effect burden	122	Application to other areas	146
Applications to other therapeutic areas	123	Other agents of interest	146
Other agents of interest	123	Mini-dictionary of terms	146
Mini-dictionary of terms	124	Key facts	146
Key facts	124	Summary points	147
Summary points	124	References	147
Acknowledgments	124	<b>14. Astrocyte-neuron lactate shuttle and pain</b>	
Conflict of interest	124	<i>Keisuke Miyamoto and Masahiro Ohsawa</i>	
References	124	Introduction	151
Further reading	127	Applications to other areas	154
<b>12. Extrasynaptic <math>\alpha</math>5GABA<sub>A</sub> receptors and their role in nociception and pathological pain</b>		Other agents of interest	154
<i>Úrzula Franco-Enzástiga, Yarim E. De la Luz-Cuellar, Luis Eduardo Hernández-Reyes, Guadalupe Raya-Tafolla, Jorge E. Torres-López, Janet Murbartián, Vinicio Granados-Soto, and Rodolfo Delgado-Lezama</i>		Mini-dictionary of terms	156
Introduction	129	Key facts	157
GABA <sub>A</sub> receptors	130	Key facts of astrocyte-neuron lactate shuttle	157
		Summary points	157
		References	157

<b>15. Nociception and sweet solutions: Applications to inflammatory pain</b>			
<i>Khawla Q. Nuseir, Manal Kassab, and Ahmad Altarifi</i>			
Introduction	161		
Inflammatory pain pathways	162		
Pain behaviors and assessment	163		
Use of sweet solutions for inflammatory pain	163		
Mechanisms of sweet solutions for inflammatory pain	164		
Sweet tasting solutions used for analgesia	164		
Clinical applications	164		
Importance of treatment of neonatal pain	165		
Applications to other areas	165		
Other agents of interest	165		
Other agents of interest	166		
Mini-dictionary of terms	166		
Key facts	166		
Key facts of prematurity	166		
Summary points	166		
References	167		
<b>16. Interlinking interleukin-33 (IL-33), neuroinflammation and neuropathic pain</b>			
<i>Camila Rodrigues Ferraz, Fernanda Soares Rasquel-Oliveira, Sergio Marques Borghi, Anelise Franciosi, Thacyana Teixeira Carvalho, Telma Saraiva-Santos, Nayara Anitelli Artero, Rubia Casagrande, and Waldiceu A. Verri, Jr.</i>			
IL-33	172		
Neuropathic pain and glial cells	173		
IL-33 and glial cells	174		
Oligodendrocytes	174		
Microglia	175		
Astrocytes	176		
Applications to other areas	176		
Other agents of interest	177		
Mini-dictionary of terms	177		
Key facts of IL-33 in neuropathic pain	177		
Summary points	178		
Funding	178		
References	179		
<b>17. Neurons of the parabrachial nucleus, nociceptive input, and pain pathways</b>			
<i>Yosuke Arima, Yoshinori Otani, and Masashi Fujitani</i>			
Introduction	184		
Anatomy of the PBN	185		
Afferent pain transmitting pathways to the LPB	186		
Nociceptive neurons in the LPB and their aversive pathway to amygdala and bed nucleus of the stria terminalis (BNST)	186		
CGRP-positive neurons in the PBN	187		
Nociceptive neurons in the LPB and their autonomic connection with the hypothalamus	187		
Pain-modulating pathways from the LPB	187		
Conclusion	188		
Applications to other areas	188		
Mini-dictionary of terms	189		
Summary points	189		
References	189		
<b>18. Anterior cingulate cortex, pain perception, and pathological neuronal plasticity during chronic pain</b>			
<i>Fernando Kasanetz, Mario A. Acuña, and Thomas Nevian</i>			
Introduction	193		
ACC is a critical hub linking neuronal circuits for nociception and emotion	194		
ACC activation is associated with the affective component of pain	194		
ACC neuronal activity mediates pain-induced negative affect	195		
Nociception-related neurons in the ACC	196		
Distinct cortical representation of acute and chronic pain	197		
Pathological neuronal plasticity in the ACC associated to chronic pain	198		
Applications to other areas	198		
Interfering with pathological cortical plasticity as a therapeutic approach for chronic pain	198		
Other agents of interest	199		
Anterior insular cortex and pain affect	199		

Mini-dictionary of terms	200	Key facts of glucagon-like peptides	223
Key facts	200	Summary points	223
Key facts of neuronal plasticity in health and disease	200	References	223
Summary points	200		
References	201		
<b>19. Sleep deprivation, headache, and Fos immunohistochemistry</b>		<b>21. Pain transmission and peripheral group III metabotropic glutamate receptors (mGluRs)</b>	
<i>Seonghoon Kim and Jeong-wook Park</i>		<i>Eui Ho Park and Hee Chul Han</i>	
Introduction	203	Introduction	228
Pain, headache, and sleep deprivation	203	Glutamate metabolism in peripheral nervous system	228
The pathophysiological relationship between sleep deprivation and headache	204	Glutamate release and pain	228
Modulation of headache and sleep-wake cycles	204	Glutamate receptor signaling: iGluR and mGluR	229
Headache	204	Localization of peripheral group III mGluR	229
Sleep	205	Negative modulation of pain transmission	230
Pharmacologic relationships between headache and sleep	205	Group III mGluRs in non-neuronal glial cells	233
Adenosine	205	Applications to other areas	234
Orexin	206	Other agents of interest	235
Melatonin	207	Mini-dictionary of terms	235
Pituitary adenylate cyclase activating peptide (PACAP)	207	Key facts of <i>activity-dependent inhibition</i>	235
Experimental research to examine headache and sleep deprivation	207	Summary points	235
Fos-immunohistochemistry	207	References	236
Animal model of sleep deprivation	208		
Animal model of headache (activation of the trigeminovascular system)	210	<b>22. TRPM8 receptor and menthol in pain management</b>	
Experimental studies of sleep deprivation and headache pain	211	<i>Hannu Kokki and Merja Kokki</i>	
Applications to other areas	213	Introduction	239
Mini-dictionary of terms	213	Transient receptor potential channels	240
Key facts	213	Menthol	240
Key facts of sleep deprivation and headache	213	Multimodal pain therapy	241
Summary points	213	Posttraumatic and postoperative pain	244
References	213	Musculoskeletal pain	244
		Neuropathic pain	245
<b>20. Antinociceptive glucagon-like peptides</b>		Headache and migraine	246
<i>Duygun Altıntaş Aykan</i>		Pregnant and lactating women	246
Introduction to the glucagon-like peptides	218	Children and adolescent	247
Applications to other areas	218	Elderly	247
Glucagon-like peptide-1 and its analogs	219	Obesity	247
Glucagon-like peptide-2	221	Other agents of interest	247
Other agents of interest	222	Applications to other areas	248
Mini-dictionary of terms	223	Mini-dictionary of terms	248
		Key facts of TRPM8 receptor and menthol	249
		Summary points	249
		References	249
		Further reading	251

## Part II Physiology, imaging and physical recordings

### 23. Anesthetic and proconvulsant effects of ketamine on EEG

*Shaila Gowda and Charles Akos Szabó*

Introduction	255
Ketamine effects as anesthetic	256
Ketamine effects as proconvulsant	257
EEG analysis of ketamine effects	257
Scalp vs intracranial EEG effects of ketamine in nonhuman primate model of an idiopathic generalized epilepsy	258
Effects of other agents on EEG	259
Key facts of anesthetic and proconvulsant effects of ketamine on EEG	261
Summary points	261
References	261

### 24. Electroencephalography and anesthetic doses of ketamine

*Logan Voss and Jamie Sleigh*

Introduction	265
Spectral EEG changes	265
Connectivity metrics	267
Neurophysiological underpinnings of the EEG effects of ketamine	268
Interactions between ketamine and other hypnotic drugs	269
Applications to other areas	270
Other agents of interest	270
Mini dictionary of terms	271
Key facts	271
Summary points	271
References	272

### 25. Linking heart function and analgesia

*Giorgia Saltelli, Antonella Paladini, Martina Rekatsina, and Giustino Varrassi*

Introduction	275
Analgesic drugs	276
Opioids	276
NSAIDs	277
Paracetamol	282
Application to other areas: Effects of NSAIDs on the kidney	282

Other agents of interest: Adjuvants	282
Mini-dictionary of terms	283
Summary points	284
References	284

### 26. Computed tomography-guided procedures for epidural injections

*Rohit Aiyer and Semih Gungor*

Introduction	287
General principles and technique common to all types of CT-guided epidural injections	287
Patient positioning	287
Three phases of CT-guided interventions	287
Epidural injections	289
Interlaminar epidural injections	290
Cervical transforaminal epidural steroid injections	290
Thoracic transforaminal epidural steroid injections	291
Lumbar transforaminal steroid injections	292
Radiation safety	294
Complications	294
Conclusion	295
Applications to other areas	295
Other agents of interest	295
Mini-dictionary of terms	296
Key facts	296
Summary points	296
References	296

### 27. Chronic pain: Linking deep brain stimulation and sensory functional MRI

*Witold H. Polanski and Johann Klein*

Introduction	299
History of deep brain stimulation for chronic pain	299
Central pain processing	300
Modern visualization of DBS targets	301
Application to other areas	302
Other methods of interest	302
Mini-dictionary of terms	303
Key facts	303
Key facts of deep brain stimulation	303
Key facts of sensory functional MRI	303
Key facts of diffusion tensor imaging (DTI)	304
Summary points	304
References	304



<b>28. Neurocognition and placebo analgesia: Linking in functional magnetic resonance imaging</b>			
<i>Sara Palermo</i>			
Introduction	307	The sequence of steps to perform neuroscience studies using fNIRS	326
Understanding the placebo effect: From the biological approach to the advent of neuroimaging techniques	308	Dynamic trace pattern evoked by electrical stimulation	327
Pain modulatory mechanisms relevant for the neuroimaging study of PA	309	Applications of fNIRS in pain research	327
Pain and nociceptive stimuli in neuroimaging study of PA	309	fNIRS and cortical connectivity in pain research	330
Pain evaluation and temporal phases in neuroimaging study of PA	310	Remarks and future directions	331
Sample characteristic relevant for the neuroimaging study of PA	310	Applications to other areas	331
Neurocognitive predictors in neuroimaging study of PA: Attention, expectation, and reappraisal	311	Mini-dictionary of terms	332
The neuroimaging meta-analytic approach to the study of PA and related neurocognitive factors	312	Key factors related to fNIRS	332
Neuroimaging findings in the study of PA in Alzheimer's disease	313	Summary points	332
Future directions	313	References	333
Applications to other areas	313	<b>30. Muscle origins of myofascial pain syndrome</b>	
Other agents of interest	314	<i>Eva María Martínez-Jiménez, Daniel López-López, Carlos Romero-Morales, Victoria Mazoterias-Pardo, Marta Elena Losa-Iglesias, David Rodríguez-Sanz, Marta San-Antolín-Gil, Ricardo Becerro-de-Bengoa-Vallejo, and César Calvo-Lobo</i>	
Mini-dictionary of terms	314	Introduction	337
Key facts of functional magnetic resonance imaging	314	Nociception in muscle tissue	338
Summary points	315	Referred pain and peripheral sensitization process	339
References	315	Sympathetic facilitation of muscle pain	339
<b>29. Linking the cortex, functional spectroscopy, and pain: Features and applications</b>		Central sensitization	339
<i>Wolnei Caumo, Janete S. Bandeira, and Jairo Alberto Dussan-Sarria</i>		Clinical applications	342
Basic concepts	320	Conclusion	342
Cortical functions related to pain processing	320	Application to other areas	342
Role of the motor cortex in pain processing	321	Other agents of interest	342
Role of the PFC in pain processing	322	Mini-dictionary of terms	342
Nature of brain regions recruited during pain: Insights from human imaging studies	322	Key facts of myofascial pain	343
The biological rationale behind near-infrared spectroscopy	322	Summary points	343
fNIRS neuroimaging: Technical aspects, advantages, limitations, and applications	323	References	343
		<b>Part III</b>	
		<b>Psychology and behavior</b>	
		<b>31. Behavioral markers of pain: Understanding the cognitive, motor, and societal interactions in the pain experience</b>	
		<i>S.A. Holmes, A. Quinlan, and M.E. Pierce</i>	
		Psychology and cognition	349
		Fear avoidance	349
		Pain catastrophizing	349
		Cognitive performance	350

Comorbidities and chronic pain	350	Neurobiological and neurochemical mechanisms of placebo analgesia and nocebo hyperalgesia	377
Motor behavior	351	The relevance of placebo and nocebo effects for pain treatment in clinical practice	380
Motor response to pain	351	Applications to other areas	382
Changing our motor behaviors	351	Placebo and nocebo phenomena related to nonopioid drugs and implications for pain treatment	382
Social interactions and pain behavior convention	352	Other agents of interest	382
Social interaction	352	Role of cognitive behavioral therapy in placebo/nocebo and pain treatment	382
Community structure—Access to resources	353	Mini-dictionary of terms	383
Biological sex and gender	353	Key facts of placebo analgesia	383
What is coming in the next 5–10 years?	354	Key facts of nocebo hyperalgesia	384
Conclusion	354	Summary points	384
Application to other areas	355	References	385
Other agents of interest	355		
Mini-dictionary of terms	355		
Key facts	355		
Summary points	356		
References	356		
<b>32. Adverse life events, sensitization of spinal nociception, and chronic pain risk</b>		<b>34. Nociception-related behavioral phenotypes in adult zebrafish</b>	
<i>Jamie L. Rhudy and Natalie Hellman</i>		<i>Fabiano V. Costa, Luiz V. Rosa, Allan V. Kalueff, and Denis B. Rosemberg</i>	
Adverse life events: A definition	359	Introduction	387
Adverse life events and health	359	Nociception and pain in animal models	387
Adverse life events and chronic pain	359	Zebrafish as animal model for translational pain research	388
The impact of adversity (stress) on nociception in animals	360	Zebrafish-based pain models	389
Pain systems and their assessment in humans	360	Applications to other areas	390
Adversity and pain processing in humans	361	Other agents of interest	390
Adversity, latent sensitization, and pain risk	368	Mini-dictionary of terms	391
Implications and future directions	369	Key facts	391
Summary	370	Key facts of zebrafish	391
Applications to other areas	371	Summary points	391
Other agents of interest	371	References	391
Mini-dictionary of terms	371		
Key facts about adversity	371	<b>35. Pain, implantable pain devices, and psychosocial aspects of pain</b>	
Summary points	371	<i>Vishal Varshney, Thomas Rutledge, Maya D'Eon, and Krishnan Chakravarthy</i>	
Conflict of interest	372	Anatomy of pain pathways	395
References	372	Psychosocial aspects of neuropathic pain	396
<b>33. Cognitive-affective modulation of pain: The placebo and nocebo phenomena and their impact on pain treatment</b>		Rationale for psychosocial evaluations	397
<i>Sergiu Albu, Hans Linsenhardt, and Mary W. Meagher</i>		Effect of spinal cord stimulation on pain processing	398
Introduction	375	Effects of modes of stimulation on psychosocial aspects of pain	399
Psychological mechanisms of placebo analgesia and nocebo hyperalgesia	376	Conclusions	400
		Application to other areas	401
		Other agents of interest	401
		Mini-dictionary of terms	401

Key facts of pain, implantable devices, and psychosocial aspects of pain	401	Other agents of interest	412
Summary points	402	Mini-dictionary of terms	412
References	402	Key facts of myofascial pain	412
		Summary points	412
		References	412
<b>36. Influence of psychological factors on myofascial pain</b>			
<i>Marta San-Antolín-Gil, Daniel López-López, Ricardo Becerro-de-Bengoa-Vallejo, Marta Elena Losa-Iglesias, Carlos Romero-Morales, David Rodríguez-Sanz, Victoria Mazoterias-Pardo, Eva María Martínez-Jiménez, and César Calvo-Lobo</i>			
Introduction	405		
Myofascial trigger point types	405		
Relationship between psychological factors and myofascial pain	406		
Personality traits and myofascial pain	406		
Anxiety and myofascial pain	408		
Depression and myofascial pain	409		
Catastrophism and myofascial pain	409		
Pain fear-avoidance and kinesiophobia and myofascial pain	410		
Central sensitization and myofascial pain	411		
Clinical applications	411		
Application to other areas	412		
		<b>Part IV</b>	
		<b>Resources</b>	
		<b>37. Recommended resources, sites, and research groups for the neuroscience of anesthetics and analgesics</b>	
		<i>Rajkumar Rajendram, Vinood B. Patel, and Victor R. Preedy</i>	
		Introduction	419
		Resources	420
		Applications to other areas	420
		Mini-dictionary of terms	424
		Key points	425
		Summary points	425
		Acknowledgments	425
		References	426
		Index	427